FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	s)														
1. Name and Address of Reporting Person *- Yorke Justin W			2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner						
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 01/27/2022						Office	er (give title belo	ow)	Other (specify	below)		
(Street) HANOVER, MD 21076			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
)	(State)	(Zip)		T	able I	- Non	-Der	ivative	Securitie	s Acqu	ired, Disp	osed of, or l	Beneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)			Code (Instr. 8)		etion			of (D)	(D) Beneficially Owner		d Following	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
					Co	ode	V	Amoun	(A) or t (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
ı Stock		01/27/2022			S	S		1,854	D	\$ 3.3	532,563	3		I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC
Stock											9,323			D	
Report on a s	separate line fo	or each class of secur	rities benefi	cially o	wned o		Pers	ons whained i	no respo n this fo	rm are	e not requ	uired to res	spond unle	ess	1474 (9-02)
											lly Owned				
Derivative Conversion Date		3A. Deemed Execution Da any	4. Transaction Code ear) (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Ame Und Seco	ount of lerlying urities tr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form o Derivat Security Direct (or Indir	Ownersh (Instr. 4) D) ect	
			Cod	de V	(A)	(D)				on Title	or				
	d Address of stin W CESSA P CESSA P COCA COCCA C	Stin W (First) (CESSA PHARMACI (80 COCA COLA DRI (Street) ER, MD 21076 (State) (State) (Stock Report on a separate line for concentration of the concen	and Address of Reporting Person* stin W OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) ER, MD 21076 OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) ER, MD 21076 OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) 2. Transaction Date (Month/Day/Year) Table II - OCESSA Conversion OCENTERION OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) 2. Transaction Date (Month/Day/Year) Table II - OCESSA OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) Tansaction Date (Month/Day/Year) Table II - OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) Table II - OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) Table II - OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) Table II - OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) Table II - OCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Month/Day/Year)	ad Address of Reporting Person* Stin W (First) (Middle) (DCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) (Street) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date Execution any (Month/Day (Month/Day 2. Transaction Date Execution any (Month/Day (Month/Day 2. Transaction Date Execution any (Month/Day (Month/Day (E.g., puts, any (Month/Day/Year) 2. Trable II - Derivative (E.g., puts, any (Month/Day/Year) (Inst	at Address of Reporting Person* Strin W	2. Issuer Name and Ti Processa Pharmace 3. Date of Earliest Trans 01/27/2022 3. Date of Earliest Trans 01/27/2022 4. If Amendment, Date ER, MD 21076 (Street) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Stock 01/27/2022 3. Transaction Date (Month/Day/Year) 2. Table II Execution Date, if conditions of Exercise Pharmace Table II - Derivative Securities Acega, puts, calls, warrant of Exercise (Month/Day/Year) 2. Table II - Derivative Securities Acega, puts, calls, warrant of Exercise (Month/Day/Year) 3. Transaction Date Execution Date, if of Transaction Code (Month/Day/Year) (Month/Day/Year) 3. Transaction Code (Inst. 8) 5. Transaction Code (Inst. 8) 6. Security 1. Stock 1. Stock 1. Stock 1. Stock 1. Stock 1. Stock 2. Transaction Code (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	2. Issuer Name and Ticker (Processa Pharmaceutical Models) (Middle) (Middle) (Middle) (CESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106 (Street) 4. If Amendment, Date Origin (ER, MD 21076 (State) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Stock (Instr. 8) (Code (Instr. 8) (Instr. 8) (Month/Day/Year) (Month/Day/Y	2. Issuer Name and Ticker or Tre Processa Pharmaceuticals, Is 10/127/2022 3. Date of Earliest Transaction (Month/Day/Year) (Street) 4. If Amendment, Date Original File File File File File File File Fil	Address of Reporting Person strin W Comparison Compa	Address of Reporting Person strin W Strin W (First)	Stock O1/27/2022 Suser Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]	Address of Reporting Person.* Code V Amount Contained in this form are not responded in this form are not reprice of Derivative Securities Conversion Date Conversion Conversion Date Conversion Date Conversion Date Con	Address of Reporting Person ** 2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA] 3. Date of Farliest Transaction (Month/Day/Year) (Check (Chec	Address of Reporting Person 2 2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceutricals, Inc. [PCSA] Processa Pharmaceutricals, Inc. [PCSA] No. (Check all appli O/27/2022 4. If Amendment, Date Original Filed(Moeth/Day/Year) O/27/2022 4. If Amendment, Date Original Filed(Moeth/Day/Year) O/27/2022 4. If Amendment, Date Original Filed(Moeth/Day/Year) O/27/2022 5. Table 1 - Non-Derivative Securities Acquired (Instr. 3, 4 and 5) O/27/2022 5. Individual or Joint/Group Filing X, Even filed by One Reporting Person From filed by One Reporting Person Officer (piper site below) O/27/2022 5. Individual or Joint/Group Filing X, Even filed by One Reporting Person From Filed Person From filed by One Reporting Person From Filed Per	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaccuticals, Inc. [PCSA] OCESA PHARMACEUTICALS, SO COCA COLA DRIVE, SUITE 106 Size of State of Fairliest Transaction (Month/Day/Year) OCESA PHARMACEUTICALS, SO COCA COLA DRIVE, SUITE 106 Size of State of State of Fairliest Transaction (Month/Day/Year) OCESA PHARMACEUTICALS, SO COCA COLA DRIVE, SUITE 106 Size of State of State of Fairliest Transaction (Month/Day/Year) OCES OCES OCES OCES OCES OCES OCES OCES

Reporting Owners

	Relationships					
	Director	10% Owner	Officer	Other		
Reporting Owner Name / Address						

orke Justin W O PROCESSA PHARMACEUTICALS, INC 80 COCA COLA DRIVE, SUITE 106 ANOVER, MD 21076

Signatures

/s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact	01/31/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$3.26 to \$3.37, inclusive. The Reporting (1) Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission,

upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.